Sarizotan

As a common neurodegenerative disease, Parkinson's disease is accompanied by motor disorder complications that occur with disease progression, which seriously affect the quality of life of patients. Existing dopaminergic treatment regimens often induce adverse reactions such as dyskinesia, and there has been a long-standing unmet clinical treatment need. Sarizotan is a selective 5-HT1A receptor partial agonist. It reduces abnormal fluctuations in dopamine release by regulating the central serotonergic neural pathway, while alleviating levodopa treatment-related dyskinesia and improving the anxiety symptoms associated with Parkinson's disease patients. It is mainly used for adjuvant treatment of motor complications of Parkinson's disease, and is suitable for adult patients who develop dyskinesia after receiving levodopa treatment.

At present, the selection of therapeutic drugs for Parkinson's disease dyskinesia is very limited worldwide. As a potential innovative therapeutic variety in this field, sarizotan has not been officially approved for marketing in major global markets, and there are no publicly verifiable statistical results on relevant market size and growth data. Among the current global R&D pipelines, except for the clinical trials promoted by the original research enterprise, few generic drug companies have arranged for relevant development, and the overall competitive landscape has not yet been formed.

The original research enterprise of sarizotan is Servier of France, and the original research trade name is Sarizotan. At present, its compound patent has expired the protection period. The main dosage form developed by the original research is oral tablet, with specifications including 5mg and 10mg, which has not been included in the Chinese *Catalogue of Chemical Drugs* and the FDA Reference Listed Drug Catalog. Up to now, there is no registered DMF registration number for sarizotan API in China, and no relevant preparation varieties have been approved for marketing in China. (Data as of July 2024, please refer to the official CDE website for the latest information)

In response to the R&D and quality control needs of sarizotan, CATO can provide a full set of impurity reference standards for this API. Most products are in stock, and in-stock products ordered before 16:00 will be shipped on the same day. They fully comply with the regulatory requirements of the Chinese Pharmacopoeia, FDA and other regulations, and can provide stable reference standard support for pharmaceutical enterprises in drug R&D, quality research and registration declaration.